Meta-AnalysisPubMed ID: 33974558·2021

Meta-Analysis: GLP-1 Receptor Agonists and Cardiovascular Outcomes

Verma S, Bhatt DL, Bain SC, et al.

Circulation, 2021

Key finding

GLP-1 agonists reduced major adverse cardiovascular events by 12% (RR 0.88, 95% CI 0.81-0.96) and cardiovascular death by 14% (RR 0.86).

Summary

Comprehensive meta-analysis of 7 major RCTs evaluating cardiovascular effects of GLP-1 agonists including semaglutide.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT